Clinical Trials Directory

Trials / Suspended

SuspendedNCT01929239

Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning

Phase Ia/Ib Trial of Anti-PSMA Designer T Cells in Prostate Cancer After Non-Myeloablative Conditioning

Status
Suspended
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
12 (estimated)
Sponsor
Roger Williams Medical Center · Academic / Other
Sex
Male
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This is a Phase Ib Pilot study of anti-PSMA designer T cells in metastatic prostate cancer. Subjects will receive escalating doses of T cells, with either low or moderate dose Interleukin 2. The T cells are collected by pheresis and then genetically modified, and given in a one time infusion.

Conditions

Interventions

TypeNameDescription
DRUGAnti-PSMA Designer T Cells

Timeline

Start date
2006-03-01
Primary completion
2017-12-01
Completion
2018-12-01
First posted
2013-08-27
Last updated
2016-06-17

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01929239. Inclusion in this directory is not an endorsement.

Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning (NCT01929239) · Clinical Trials Directory